Meta-hlorofenilpiperazin
![]() |
|||
![]() |
|||
(IUPAC) ime | |||
---|---|---|---|
1-(3-hlorofenil)piperazin | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 6640-24-0 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 1355 | ||
ChemSpider[3] | 1314 | ||
ChEBI | CHEBI:10588 ![]() |
||
ChEMBL[4] | CHEMBL478 ![]() |
||
Hemijski podaci | |||
Formula | C10H13ClN2 | ||
Mol. masa | 196,676 g/mol | ||
SMILES | eMolekuli & PubHem | ||
|
|||
Farmakokinetički podaci | |||
Metabolizam | Hepatic | ||
Poluvreme eliminacije | 2-6 sata | ||
Izlučivanje | Renalno | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | |||
Način primene | Oralno, nazalno, rektalno |
meta-Hlorofenilpiperazin (mCPP) je psihoaktivni lek iz fenilpiperazinske klase. On je razvijen krajem 1970-tih i korišten je u naučnim istraživanjima, pre nego što je postao dezijnirana droga sredinom 2000-tih.[5][6] mCPP je detektovan u pilulama koje su reklamirane kao legalne alternative za nedopuštne stimulanse u Novom Zelandu i u pilulama koje su prodavane kao "ekstazi" u Evropi i Sjedinjenim Državama.[7][8]
Uprkos pokušaja da se uvede u upotrebu kao rekreaciona supstanca, mCPP se zapravo generalno smatra nepoželjnim jer proizvodi neprijatna iskustva.[7] Njemu nedostaju potkrepljujući efekti,[9] proizvodi depresivne i anksiogene efekte kod glodara i ljudi,[10][11] i može da indukuje panične napade kod osoba koje su im podložne.[12][13][14][15] On takođe pogoršava opsesivno-kompulzivne simptome kod ljudi sa tim poremećajem.[16][17][18]
Vidi još[uredi - уреди | uredi izvor]
- 1-Benzilpiperazin (BZP)
- 1-Metil-4-benzilpiperazin (MBZP)
- 1,4-Dibenzilpiperazin (DBZP)
- 3-Trifluorometilfenilpiperazin (TFMPP)
- 3,4-Metilendioksi-1-benzilpiperazin (MDBZP)
- 4-Bromo-2,5-dimetoksi-1-benzilpiperazin (2C-B-BZP)
- 4-Fluorofenilpiperazin (pFPP)
- 4-Metoksifenilpiperazin (MeOPP)
- Etoperidon, Nefazodon, Trazodon - Metaboliziju se u mCPP.
- Hipazin - Srodni piperazinski serotoninski agonist.
- Org 12,962
References[uredi - уреди | uredi izvor]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.
- ↑ Bossong MG, Van Dijk JP, Niesink RJ (December 2005). "Methylone and mCPP, two new drugs of abuse?". Addiction Biology 10 (4): 321–3. PMID 16318952. doi:10.1080/13556210500350794.
- ↑ Lecompte Y, Evrard I, Arditti J (2006). "[Metachlorophenylpiperazine (mCPP): a new designer drug]". Thérapie (in French) 61 (6): 523–30. PMID 17348609.
- ↑ 7,0 7,1 Bossong M, Brunt T, Van Dijk J et al. (March 2009). "mCPP: an undesired addition to the ecstasy market". Journal of Psychopharmacology (Oxford, England) 24 (9): 1395–401. PMID 19304863. doi:10.1177/0269881109102541.
- ↑ Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ (December 2009). "Content of ecstasy in the Netherlands: 1993-2008". Addiction (Abingdon, England) 104 (12): 2057–66. PMID 19804461. doi:10.1111/j.1360-0443.2009.02707.x.
- ↑ Tancer M, Johanson CE (October 2003). "Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP". Drug and Alcohol Dependence 72 (1): 33–44. PMID 14563541. doi:10.1016/S0376-8716(03)00172-8.
- ↑ Rajkumar R, Pandey DK, Mahesh R, Radha R (April 2009). "1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay". European Journal of Pharmacology 608 (1-3): 32–41. PMID 19269287. doi:10.1016/j.ejphar.2009.02.041.
- ↑ Kennett GA, Whitton P, Shah K, Curzon G (May 1989). "Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists". European Journal of Pharmacology 164 (3): 445–54. PMID 2767117. doi:10.1016/0014-2999(89)90252-5.
- ↑ Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (November 1991). "Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects". Biological Psychiatry 30 (10): 973–84. PMID 1756202. doi:10.1016/0006-3223(91)90119-7.
- ↑ Charney DS, Woods SW, Goodman WK, Heninger GR (1987). "Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects". Psychopharmacology 92 (1): 14–24. PMID 3110824.
- ↑ Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG (October 2007). "Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 17 (10): 637–42. PMID 17481859. doi:10.1016/j.euroneuro.2007.03.005.
- ↑ van der Wee NJ, Fiselier J, van Megen HJ, Westenberg HG (October 2004). "Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 14 (5): 413–7. PMID 15336303. doi:10.1016/j.euroneuro.2004.01.001.
- ↑ Hollander E, DeCaria CM, Nitescu A et al. (January 1992). "Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers". Archives of General Psychiatry 49 (1): 21–8. PMID 1728249.
- ↑ Broocks A, Pigott TA, Hill JL et al. (June 1998). "Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results". Psychiatry Research 79 (1): 11–20. PMID 9676822. doi:10.1016/S0165-1781(98)00029-8.
- ↑ Pigott TA, Zohar J, Hill JL et al. (March 1991). "Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder". Biological Psychiatry 29 (5): 418–26. PMID 2018816. doi:10.1016/0006-3223(91)90264-M.